Levodropropizina Fg (Levodropropizine)

Levodropropizine, the active ingredient in Levodropropizina Fg, is an antitussive presented as an oral formulation for oral use. It acts on the peripheral cough reflex to reduce the frequency and intensity of dry, non‑productive coughs in both adult and pediatric patients when a symptomatic cough suppressant is indicated.

GNH USA supplies Levodropropizina Fg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels aligned to EU regulatory standards. The company ensures product quality through rigorous quality‑assurance processes and provides reliable logistics for global markets.

Levodropropizine is an antitussive that acts on the peripheral cough reflex to alleviate cough symptoms.

Dry cough: reduces frequency and severity of non‑productive coughs. Acute cough associated with upper respiratory tract infection: provides symptomatic relief. Chronic cough not caused by asthma or infection: helps control persistent cough when other causes have been excluded.

Levodropropizine may cause adverse reactions, which are generally mild but can be serious in rare cases.

Common Side Effects: - Nausea: mild stomach upset. - Dizziness: transient light‑headedness. - Taste alteration: unusual flavor perception. - Mild headache: occasional tension‑type headache.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Severe gastrointestinal disturbance: persistent vomiting or diarrhea.

Levodropropizine should be used with caution in specific populations and conditions.

Use in children: follow pediatric guidance and avoid use in infants under 2 years unless advised. Renal impairment: dose adjustment may be required in patients with reduced kidney function. Hepatic disease: caution in patients with liver dysfunction. Concomitant CNS depressants: monitor for additive sedation. Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Levodropropizine can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may increase risk of central nervous system effects. - Strong CYP450 inhibitors: could raise plasma levels of levodropropizine.

Moderate Interactions (Monitor Closely): - Antihistamines: may enhance antitussive effect, monitor for excessive sedation. - Opioid cough suppressants: additive effect on cough suppression, assess need. - Alcohol: may increase dizziness, advise moderation.